<证券交易委员会tion class="main-证券交易委员会tion pt-column-control-inverted" id="main" role="main" tabindex="-1">
<证券交易委员会tion class="container" itemprop="name">
<证券交易委员会tion class="hero-feature hero-feature--no-background l-margin">

澳门在线赌城娱乐将收购Gracell, furthering cell therapy ambition across 肿瘤学 and autoimmune diseases

<证券交易委员会tion class="container">

包括针对血液恶性肿瘤和自身免疫性疾病的临床阶段自体BCMA/CD19 CAR-T治疗, and proprietary cell therapy manufacturing platform
 

澳门在线赌城娱乐(澳门在线赌城娱乐)已达成收购Gracell生物技术公司的最终协议. (Gracell, 纳斯达克:GRCL), 一家全球临床阶段澳门第一赌城在线娱乐公司,开发用于治疗癌症和自身免疫性疾病的创新细胞疗法, furthering the 澳门在线赌城娱乐 cell therapy ambition.

此次收购将丰富澳门在线赌城娱乐不断增长的细胞疗法产品线, 一本小说, 临床阶段的BCMA和CD19双靶向自体嵌合抗原受体t细胞(CAR-T)治疗, 多发性骨髓瘤的潜在新疗法, 以及其他血液恶性肿瘤和自身免疫性疾病,包括系统性红斑狼疮(SLE).

自体CAR-T是一种细胞疗法,通过重新编程患者的免疫T细胞来靶向致病细胞, and the manufacturing process for this type of treatment is complex and time-consuming. The Gracell FasTCAR platform significantly shortens manufacturing time, 增强T细胞适应性, 并且有可能提高患者自体CAR-T治疗的有效性. Future applications of this technology may also include rare diseases.

Susan Galbraith, Executive Vice President, 肿瘤学 R&D, 澳门在线赌城娱乐, 他说:“拟议收购Gracell将补充澳门在线赌城娱乐在细胞治疗方面的现有能力和先前的投资, 澳门第一赌城在线娱乐在实体肿瘤的CAR-T和t细胞受体疗法(TCR-Ts)中建立了澳门第一赌城在线娱乐的存在. GC012F will accelerate our cell therapy strategy in haematology, 有机会通过差异化制造工艺为血癌患者带来潜在的一流治疗, 以及探索细胞疗法在自身免疫性疾病中重置免疫反应的潜力.”

Dr. 威廉·曹, 创始人, 董事长兼首席执行官, Gracell, 他说:“澳门第一赌城在线娱乐期待与澳门在线赌城娱乐合作,加速实现澳门第一赌城在线娱乐的共同目标,为更多患有衰弱性疾病的患者带来变革性细胞疗法. 通过结合澳门第一赌城在线娱乐的专业知识和资源, we can unlock new ways to harness the Gracell FasTCAR manufacturing platform, 澳门第一赌城在线娱乐认为有潜力优化工程化T细胞的治疗特性, to pioneer the next generation of autologous cell therapies.”

Gracell will operate as a wholly owned subsidiary of 澳门在线赌城娱乐, 在中国和美国都有业务.

金融方面的考虑
根据最终协议的条款, 澳门在线赌城娱乐将通过合并以2美元的价格收购Gracell的全部稀释股本(包括ads代表的股份).00 per ordinary share in cash at closing (equivalent to $10.00 per ADS of Gracell) plus a non-tradable contingent value right of $0.每普通股30美元(相当于1美元).在达到规定的监管里程碑后支付现金(每股Gracell ADS 50美元).

对价的预付现金部分代表约1美元的交易价值.0bn, a 62% premium to Gracell’s closing market price on 22nd 较60天成交量加权平均价格(VWAP) 3美元溢价154%.94在此公告之前. 结合, the upfront and potential contingent value payments represent, 如果实现, 交易价值约为1美元.2bn, an 86% premium to Gracell's closing market price on 22nd December 2023 and a 192% premium to the 60-day VWAP. 作为交易的一部分, 澳门在线赌城娱乐将获得这笔现金, cash equivalents and short-term investments on Gracell’s balance sheet, 总共234美元.截至2023年9月30日.

The transaction is expected to close in the first quarter of 2024, 以惯例成交条件为准, 包括监管许可, 和Gracell股东的批准. The transaction does not impact 澳门在线赌城娱乐’s financial guidance for 2023.

笔记

关于GC012F
GC012F是Gracell公司的FasTCAR-enabled BCMA/CD19双靶向自体CAR-T细胞疗法, 它的目标是通过寻求驱动深度和持久的反应并提高安全性来改变癌症和自身免疫性疾病的治疗. GC012F目前正在多种血液恶性肿瘤和自身免疫性疾病的临床研究中进行评估. Gracell已经在美国启动了一项评估GC012F治疗复发或难治性多发性骨髓瘤的Ib/II期试验.

澳门在线赌城娱乐在血液学
澳门在线赌城娱乐 is pushing the boundaries of science to redefine care in haematology. We have expanded our commitment to patients with haematologic conditions, not only in 肿瘤学 but also in rare diseases with the acquisition of Alexion, allowing us to reach more patients with high unmet needs. By applying our deep understanding of blood cancers, 利用澳门第一赌城在线娱乐在实体肿瘤肿瘤学方面的优势,并秉承Alexion在补体科学方面的开创性传统,为罕见疾病提供创新药物, 澳门第一赌城在线娱乐正在追求针对疾病潜在驱动因素的新疗法的端到端开发.

By targeting haematologic conditions with high unmet medical needs, we aim to deliver innovative medicines and approaches to improve patient outcomes. Our goal is to help transform the lives of patients living with malignant, 罕见病和其他相关血液病, 由患者的见解塑造, caregivers and physicians to have the most meaningful impact.

澳门在线赌城娱乐在 肿瘤学
澳门在线赌城娱乐正在引领肿瘤学领域的一场革命,致力于为各种形式的癌症提供治疗, following the science to understand cancer and all its complexities to discover, develop and deliver life-changing medicines to patients.

The Company's focus is on some of the most challenging cancers. 正是通过持续的创新,澳门在线赌城娱乐建立了行业中最多样化的产品组合和管道之一, 有可能催化医学实践的变化,改变病人的体验.

澳门在线赌城娱乐 has the vision to redefine cancer care and, 有一天,, 消除癌症作为死亡原因.

澳门在线赌城娱乐在 澳门第一赌城在线娱乐: 呼吸 and 免疫学
呼吸 & 免疫学, 澳门在线赌城娱乐澳门第一赌城在线娱乐公司的一部分, is a key disease area and growth driver to the Company.

澳门在线赌城娱乐是呼吸系统护理领域的领导者,拥有50年的历史,并在免疫介导疾病方面拥有不断增长的药物组合. The Company is committed to addressing the vast unmet needs of these chronic, 常常使人衰弱的, diseases with a pipeline and portfolio of inhaled medicines, biologics and new modalities aimed at previously unreachable biologic targets. 澳门第一赌城在线娱乐的目标是提供改变生活的药物,帮助消除COPD这一主要死亡原因, eliminate asthma attacks and achieve clinical remission in immune-mediated diseases.

With common pathways and underlying disease drivers across respiratory and immunology, 澳门在线赌城娱乐正在跟踪从慢性肺部疾病到免疫驱动疾病领域的科学. 该公司在免疫学领域的业务日益增长,主要集中在五个具有多疾病潜力的中后期特许经营权, in areas including rheumatology (including SLE), 皮肤病学, 胃肠病学, 以及系统性嗜酸性粒细胞引起的疾病. 澳门在线赌城娱乐在呼吸系统领域的雄心 & 免疫学是实现疾病的改变和持久缓解数以百万计的世界各地的患者.

附加信息和在哪里可以找到它
与拟议的交易有关, Gracell打算向美国证券交易委员会(“SEC”)提交或提供相关材料。, 包括代理声明. Promptly after the proxy statement is filed or furnished with the SEC, 公司将邮寄或以其他方式向有权在临时股东大会上就拟议交易投票的每位股东提供委托书和委托卡. 本通讯不能替代代理声明或Gracell可能向SEC提交或提供或发送给其股东的与拟议交易相关的任何其他文件. 在作出任何投票决定之前, 澳门第一赌城在线娱乐敦促格雷斯尔的股东阅读这些材料(包括其任何修订或补充)以及与拟议交易有关的任何其他相关文件,这些文件将在格雷斯尔提交或提供给美国证券交易委员会时可用,因为它们将包含有关拟议交易和拟议交易各方的重要信息. 委托书及与拟议交易有关的其他相关材料(可得时), and any other documents filed or furnished with the SEC by the Company, may be obtained free of charge at the SEC’s website at www.证券交易委员会.或Gracell的网站www.gracellbio.com.

本次征集的参与者
This announcement is neither a solicitation of proxy, 购买任何证券的要约或出售任何证券的要约的征求,并不能替代任何代理声明或在交易进行时可能向美国证券交易委员会提交的其他文件. 澳门在线赌城娱乐, Gracell and certain of their respective directors, executive officers and other members of management and employees may, 根据SEC的规定, 应被视为就拟议的交易向Gracell的股东征求代理权的“参与者”. 在向美国证券交易委员会提交或提供的代理声明中,将在与交易相关的代理声明中列出可能被视为“参与者”的人员信息. 有关这些潜在参与者利益的其他信息将包括在代理声明和其他相关文件中,当这些文件可用时,将提交或提供给SEC.

前瞻性陈述
This announcement may include statements that are not statements of historical fact, 或"前瞻性陈述",” including with respect to 澳门在线赌城娱乐’s proposed acquisition of Gracell. 此类前瞻性陈述包括, 但不限于, 澳门在线赌城娱乐和格雷斯尔完成收购协议所设想的交易的能力, 包括双方满足合并协议中规定的条件的能力, statements about the expected timetable for completing the transaction, 澳门在线赌城娱乐和Gracell的信念和期望以及关于澳门在线赌城娱乐拟议收购Gracell所寻求的利益的陈述, the potential effects of the acquisition on both 澳门在线赌城娱乐 and Gracell, the possibility of any termination of the merger agreement, as well as the expected benefits and success of [GC012F and any combination product]. 这些陈述基于澳门在线赌城娱乐和Gracell管理层当前的信念和期望,并受到重大风险和不确定性的影响. 不能保证拟议交易的完成条件将在预期的时间表上得到满足,也不能保证[GC012F将获得必要的监管批准,或在获得批准后证明商业成功]. If underlying assumptions prove inaccurate or risks or uncertainties materialise, 实际结果可能与前瞻性陈述中所述的结果有重大差异. 风险和不确定性包括, 但不限于, uncertainties as to the timing of the merger; uncertainties as to how many of Gracell’s shareholders will vote in favour of the merger; the possibility that various conditions to the consummation of the merger contemplated by the merger agreement may not be satisfied or waived; the ability to obtain necessary regulatory approvals or to obtain them on acceptable terms or within expected timing; the effects of disruption from the transactions contemplated by the merger agreement and the impact of the announcement and pendency of the transactions on Gracell’s business; the risk that shareholder litigation in connection with the offer or the merger may result in significant costs of defence, indemnification and liability; the possibility that the achievement of the specified milestone described in the contingent value rights agreement may take longer to achieve than expected or may never be achieved and the resulting contingent milestone payment may never be realised; general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of COVID-19; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; competition from other products; and challenges in在这里nt in new product 发展, 包括获得监管部门的批准.

澳门在线赌城娱乐和Gracell均不承担公开更新任何前瞻性声明的义务, 是否是新信息的结果, 未来事件或其他, 除非法律规定. 可能导致结果与前瞻性陈述中描述的结果产生重大差异的其他因素可在截至2022年12月31日的澳门在线赌城娱乐年度报告表格20-F和截至2022年12月31日的Gracell年度报告表格20-F中找到, in each case as amended by any subsequent filings made with the SEC. 澳门在线赌城娱乐和格雷斯尔向美国证券交易委员会提交的这些文件和其他文件可在www上查阅.证券交易委员会.政府.

澳门在线赌城娱乐
澳门在线赌城娱乐(LSE/STO/Nasdaq: AZN)是一家全球性制药公司, science-led biopharmaceutical company that focuses on the discovery, 发展, and commercialisation of prescription medicines in 肿瘤学, 罕见疾病, 和澳门第一赌城在线娱乐, 包括心血管, 肾 & 新陈代谢和呼吸 & 免疫学. 总部设在剑桥, UK, 澳门在线赌城娱乐在100多个国家开展业务,其创新药物被全球数百万患者使用. 请访问 澳门在线赌城娱乐.com 并在社交媒体上关注公司 @澳门在线赌城娱乐

联系人
For details on how to contact the 投资者关系 Team, please click 在这里. 对于“媒体联系人”,单击 在这里.


艾德里安·坎普
公司秘书
澳门在线赌城娱乐

 

tags

  • 肿瘤学
  • 公司和金融
<证券交易委员会tion aria-hidden="true" class="modal-window modal-window--show js-modal-window--show" data-stackable="false" id="modal-link-confirmation" role="dialog" tabindex="-1"> <证券交易委员会tion aria-hidden="true" class="modal-window modal-window--show js-modal-window--show" data-stackable="false" id="modal-generic" role="dialog" tabindex="-1">
<证券交易委员会tion aria-hidden="true" class="modal-window--show js-modal-window--show" data-stackable="false" id="hcp-popup" role="dialog" tabindex="-1">